Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

onents manufactured by us and sold to other third party medical device manufacturers who assemble those components into finished medical devices. Sales of our Base Medical Products are supported by a small group of direct sales personnel, as well as a network of independent sales representatives and medical product distributors. Sales of our Base Medical Products tend to exhibit greater volatility or slower relative growth, particularly our sales of components to third party medical device manufacturers, which may be impacted by customer concentration and the business issues that certain of our large customers may face, as well as to a more limited extent by economic and credit market conditions. Sales of our Base Medical Products declined by approximately 12% in the first quarter of 2009 as compared to the first quarter of 2008, and declined by approximately 3% as compared to the fourth quarter of 2008. Excluding the impact of foreign currency changes between the respective periods, revenue would have declined by 7% and 3% as compared to the first quarter of 2008 and the fourth quarter of 2008, respectively.

The decline in our Base Medical Products sales as compared to the first quarter of 2008 is due primarily to lower sales of medical device components to other third party medical device manufacturers, particularly sales of surgical needles to one of our largest customers, and to a more limited extent due to negative currency impact relating to sales of certain of our Base Medical Product lines outside of the United States. Manufacturing of surgical needles, as of November 2008, was fully transferred to our facility in Aguadilla, Puerto Rico from our facility in Syracuse, New York. We believe that the closure of our Syracuse production facility in November and the finalization of our move of surgical needle production to Aguadilla, combined with the difficult economic and credit market environment, may have impacted our level of Base Medical Product sales
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a designer ... & Marketing Director. , With more than 25 years of experience in ... Tronics’ business development activities worldwide. He brings to the company his strong expertise ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... 1, 2010 Amgen (Nasdaq: AMGN ) Senior ... will urge members of a U.S. Food and Drug Administration ... establish approval standards that ensure patient safety and follow a ... will follow," Dr. Miletich said.  "Amgen believes biosimilars have a ...
... PharmaNet Development Group, Inc., a leading provider of ... medical device companies, today announced its experts will share ... Annual Partnerships in Clinical Trials Conference taking place from ... At the conference, members of PharmaNet,s management ...
... BOSTON, Oct. 30 Tibotec Pharmaceuticals (Tibotec) announced today the ... analysis of the phase 2 response-guided PILLAR study in treatment-naive ... the 61st Annual Meeting of the American Association for the ... data will be presented as part of a late-breaker oral ...
Cached Biology Technology:Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 3Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 4
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Meteosat in 1977, 33 years of imagery combined with ... improve weather forecasting, with direct benefits for us. ... satellites, like Meteosat Second Generation (MSG). Today, thousands of ... use of the world,s most powerful computers. The MSG ...
... and the functions and properties of tissues and organs ... clusters have not been examined in great detail. ... Systems (EBICS) Center to be operated by the Massachusetts ... Urbana-Champaign, and the Georgia Institute of Technology intends to ...
... An extremely small RNA molecule created by a University of ... to synthesize proteins, the building blocks of life. The findings ... of Earthly life," the lead researcher contends. The ... reaction is described in a paper published this week in ...
Cached Biology News:$25M NSF center established to investigate the creation of biological machines 2$25M NSF center established to investigate the creation of biological machines 3$25M NSF center established to investigate the creation of biological machines 4U. of Colorado scientists create tiny RNA molecule with big implications for life's origins 2U. of Colorado scientists create tiny RNA molecule with big implications for life's origins 3
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
... Mouse monoclonal [HDAC8-48] to HDAC8 ... by several mechanisms such as DNA ... translational modifications of histones, which include ... epsilon-amino groups of lysine residues present ...
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: